Welcome to our dedicated page for Halozyme Thrp SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Halozyme Therapeutics, Inc. (HALO) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biopharmaceutical company, Halozyme uses Forms 10-K, 10-Q and 8-K to report on its drug delivery business, collaborations, financing activities and governance matters.
Through current reports on Form 8-K, Halozyme discloses material events such as the issuance of convertible senior notes due 2031 and 2032, amendments to its revolving credit facility, entry into and completion of the Elektrofi acquisition, significant collaboration agreements, and executive appointments or transitions. These filings often include details on note terms, capped call transactions, credit covenants and merger conditions that are not fully described in press releases.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (not reproduced here but referenced in 8-Ks) typically contain broader discussions of Halozyme’s ENHANZE, Hypercon and MDASE technology portfolios, risk factors, royalty and collaboration structures, and overall financial condition. Investors use these filings to understand how platform licensing, proprietary products and acquisitions contribute to the company’s long-term strategy.
Stock Titan enhances this information with AI-powered summaries that highlight key terms in lengthy documents, such as conversion conditions for the company’s notes, leverage and coverage ratios in its credit agreement, and the main obligations and covenants in merger contracts. Users can also review disclosures related to executive compensation arrangements, transition agreements and other governance topics reported under Item 5.02 of Form 8-K.
By combining real-time updates from EDGAR with AI-generated explanations, the Halozyme filings page helps readers quickly locate and interpret the sections of 10-Ks, 10-Qs, 8-Ks and related exhibits that are most relevant to their analysis of HALO stock.
Halozyme Therapeutics (HALO) reported stronger quarterly results. For the three months ended September 30, 2025, total revenues were $354,264,000 versus $290,084,000 a year ago, driven by royalties of $236,038,000 and product sales of $94,228,000. Net income was $175,225,000 compared to $137,011,000, with diluted EPS of $1.43 versus $1.05.
For the nine months, revenue reached $944,844,000 versus $717,316,000, and net income was $458,480,000 versus $307,079,000, reflecting broad growth in royalties and milestones. Operating cash flow was $432,529,000, supporting cash and cash equivalents of $419,665,000 at quarter end.
The company repurchased common stock using $342,372,000 year-to-date. On the balance sheet, current portion of long-term debt, net, was $710,685,000 and long-term debt, net, was $800,072,000. Shares outstanding were 117,597,000 as of October 27, 2025. Stockholders’ equity increased to $503,915,000 from $363,821,000 at December 31, 2024.
Halozyme Therapeutics, Inc. furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The release was provided as Exhibit 99.1 under Item 2.02.
The company also disclosed a planned CFO transition. Nicole LaBrosse, Senior Vice President and Chief Financial Officer, will continue as CFO until the earlier of when a new CFO is hired or March 30, 2026, after which she will depart to pursue a new professional opportunity. Halozyme has initiated a search for its next CFO.
The company stated that Ms. LaBrosse’s departure is not due to any disagreement with its independent auditors or with the company regarding financial statements, internal control over financial reporting, operations, policies, or practices. The company expects to enter into a transition and release agreement with Ms. LaBrosse.
Halozyme Therapeutics (HALO) furnished a Regulation FD update announcing it issued a statement on the final IPAY 2028 guidance for Medicare price negotiations from the U.S. Centers for Medicare & Medicaid Services. The statement includes the company’s long‑term projections of U.S. Medicare Part B spend as a percentage of total ENHANZE partner product subcutaneous sales. The statement is available on the company’s website and attached as Exhibit 99.1. This information is furnished under Item 7.01 and is not deemed filed or incorporated by reference.
Officer equity grants and option exercise reported. The reporting person, Cortney Caudill, SVP and Chief Operating Officer, acquired 9,031 shares via an option exercise with an exercise price of
HALO officer Cortney Caudill filed an initial Form 3 reporting direct ownership of 7,674 shares and equity awards that can convert to common stock. The reported awards include stock options exercisable for 89,224 and 11,302 shares with exercise prices of
Halozyme Therapeutics, Inc. reported a leadership change, appointing Cortney Caudill as Senior Vice President, Chief Operating Officer effective October 1, 2025. She previously served as the company’s Senior Vice President, Chief Operations Officer since October 2023 and has more than two decades of operational experience at multiple life sciences companies, including Aeglea Biotherapeutics and several global biotechnology and pharmaceutical organizations.
Ms. Caudill will receive an initial annual base salary of $600,000 and has a 2025 bonus target equal to 50% of her base salary under the company’s executive incentive plans. In connection with her appointment, she will receive an equity award valued at $500,000, split equally between stock options and restricted stock units, which will vest over four years under Halozyme’s standard vesting schedule. The company states there are no family relationships or related-party transactions involving Ms. Caudill in her new role.
Halozyme Therapeutics entered into an Agreement and Plan of Merger to combine with Elektrofi, Inc. under which Halozyme's wholly owned subsidiary Erraid Merger Sub Inc. will merge into Elektrofi and Elektrofi will survive as a wholly owned subsidiary of Halozyme. The filing names Shareholder Representative Services LLC as the securityholders' representative. The disclosure describes the planned corporate combination but does not disclose financial terms, timing, or regulatory approvals in the provided excerpt.
Halozyme Therapeutics (HALO) Form 144 notice reports a proposed sale of 136,569 shares of common stock through J.P. Morgan Securities, with an aggregate market value reported as $10,015,970 and an approximate sale date of 10/01/2025 on NASDAQ. The filing shows the shares were acquired on 10/01/2025 via stock option exercise and paid in cash. Recent disclosed sales by the same person, Helen Torley, list nine separate transactions from 07/08/2025 through 09/04/2025, each of 20,000 shares, with gross proceeds shown for each trade.
Halozyme Therapeutics reported that it executed an Agreement and Plan of Merger with Elektrofi, Inc., with the combination to be implemented through Erraid Merger Sub Inc.
The merger agreement is dated September 30, 2025 and names Shareholder Representative Services LLC as shareholder representative. Halozyme issued a press release on October 1, 2025 describing this transaction, which is furnished as Exhibit 99.1 to this report.
Nicole LaBrosse, SVP and Chief Financial Officer of Halozyme Therapeutics (HALO), reported two open-market sales of common stock on 09/22/2025 executed under a Rule 10b5-1 trading plan adopted on June 11, 2025. The Form 4 shows a sale of 1,913 shares at a weighted-average price of $77.827 (prices in the range $77.34–$78.32) and a sale of 314 shares at a weighted-average price of $78.667 (range $78.37–$79.18).
Following the reported transactions, the beneficial ownership reported was 22,079 shares (direct). The filing was signed on behalf of the reporting person by an attorney-in-fact on 09/23/2025. The Form 4 discloses that the sales were effected by a broker pursuant to the 10b5-1 plan and provides weighted-average price ranges with an offer to furnish per-price quantities on request.
FAQ
What is the current stock price of Halozyme Thrp (HALO)?
What is the market cap of Halozyme Thrp (HALO)?
